ARGOMENTO: US research shows Astra vaccine protects against 7

AstraZeneca Reveals Results of Long-awaited American Clinical Trials Covid-19 vaccine found of the company, developed with the University ofThug LifeOxford. Prevents 74% of symptomatic infections and increases to 83.5% for people aged 65 and over. Full FDA approval is coming soon.

This overall efficiency of 74% is lower than the interim figure of 79% reported by AstraZeneca in March. It was revised to 76% a few days after being criticized by health officials. It is a number based on outdated data.

The latest data, published by the British drug company in the New England Journal of Medicine on Wednesday (Sept. 29), are based on clinical trials involving more than 26,000 American volunteers. Chile and Peru received two doses of vaccination 1 month apart.

The report stated that No cases of COVID-19 were found with severe or critical symptoms Among the more than 17,600 subjects who received the AstraZeneca vaccine, compared with eight infected and severely or critically ill from the more than 8,500 subjects who received the placebo vaccine. The group also had two deaths, but no deaths were found in the vaccinated group.

Dr. Anna Durbin, a vaccine specialist at Johns Hopkins University, was one of the researchers in the study. expressed surprise and delighted that The overall results indicate that The AstraZeneca vaccine is very effective at preventing severe symptoms and hospitalization.

This study did not find thromboembolic events associated with low platelets. This is a rare side effect in people receiving the vaccine that AstraZeneca co-developed with researchers at the British University of Oxford.

Incidentally, at the end of July AstraZeneca revealed that Plans to apply for approval for the COVID-19 vaccine The company's chief executive, Pascal Soriet, said at the time he hoped the AstraZeneca vaccine would be available. important role in America Although the processes It took longer than expected.